Predictora | Adjusted hazard ratiob (95% CI) | ||
---|---|---|---|
ETN 50 mg + MTX n = 74 | ETN 25 mg + MTX n = 56 | MTX n = 66 | |
Loss of DAS28 remission at single time point in double-blind period | |||
Lack of sustained DAS28 remission | 2.32 (1.44, 3.73) | 2.59 (1.48, 4.55) | 1.85 (1.24, 2.77) |
Sustained weighted DAS28 remission | 0.67 (0.56, 0.80) | 0.71 (0.59, 0.86) | 0.79 (0.68, 0.92) |
DAS28 at week 36 | 2.44 (1.59, 3.73) | 2.81 (1.70, 4.63) | 1.74 (1.20, 2.51) |
DAS28 at week 40 | 3.24 (2.48, 4.23) | 5.88 (4.05, 8.53) | 2.26 (1.88, 2.71) |
Change in DAS28 from week 36 to 40 | 3.24 (2.48, 4.23) | 5.88 (4.05, 8.53) | 2.26 (1.88, 2.71) |
ESR at week 40 | 1.05 (1.02, 1.08) | 1.05 (1.02, 1.07) | 1.02 (1.01, 1.03) |
Change in ESR from week 36 to 40 | 1.09 (1.06, 1.12) | 1.07 (1.04, 1.10) | 1.02 (1.01, 1.03) |
Sustained weighted SDAI remission | 0.81 (0.58, 1.11) | 0.49 (0.30, 0.78) | 0.80 (0.60, 1.08) |
SDAI at week 40 | 1.12 (1.08, 1.16) | 1.24 (1.17, 1.32) | 1.08 (1.06, 1.11) |
Change in SDAI from week 36 to 40 | 1.13 (1.09, 1.18) | 1.23 (1.16, 1.30) | 1.09 (1.06, 1.12) |
Sustained weighted CDAI remission | 0.87 (0.65, 1.17) | 0.49 (0.32, 0.75) | 0.85 (0.64, 1.13) |
CDAI at week 40 | 1.12 (1.08, 1.16) | 1.24 (1.17, 1.31) | 1.09 (1.06, 1.12) |
Change in CDAI from week 36 to 40 | 1.13 (1.09, 1.18) | 1.23 (1.16, 1.30) | 1.09 (1.07, 1.12) |
PGA at week 40 | 1.50 (1.23, 1.81) | 1.73 (1.40, 2.12) | 1.26 (1.15, 1.39) |
Change in PGA from week 36 to 40 | 1.52 (1.23, 1.88) | 1.42 (1.10, 1.83) | 1.25 (1.13, 1.38) |
PtGA at week 40 | 1.27 (1.14, 1.42) | 1.26 (1.11, 1.43) | 1.25 (1.15, 1.36) |
Change in PtGA from week 36 to 40 | 1.28 (1.14, 1.45) | 1.49 (1.26, 1.78) | 1.28 (1.17, 1.39) |
General health VAS at week 40 | 1.03 (1.02, 1.04) | 1.02 (1.01, 1.03) | 1.02 (1.02, 1.03) |
Change in general health VAS from week 36 to 40 | 1.04 (1.02, 1.05) | 1.03 (1.02, 1.05) | 1.03 (1.02, 1.04) |
HAQ score at week 40 | 2.00 (1.31, 3.06) | 1.50 (0.94, 2.38) | 2.04 (1.47, 2.83) |
Change in HAQ score from week 36 to 40 | 2.16 (1.11, 4.20) | 3.40 (1.75, 6.59) | 3.41 (2.12, 5.46) |
TJC at week 40 | 1.15 (1.09, 1.22) | 1.46 (1.31, 1.63) | 1.22 (1.14, 1.30) |
Change in TJC from week 36 to 40 | 1.15 (1.08, 1.22) | 1.55 (1.37, 1.76) | 1.24 (1.16, 1.32) |
SJC at week 40 | 1.11 (0.98, 1.26) | 1.44 (1.26, 1.65) | 1.18 (1.09, 1.27) |
Change in SJC from week 36 to 40 | 1.31 (1.14, 1.50) | 1.40 (1.19, 1.64) | 1.23 (1.13, 1.35) |
Pain VAS at week 40 | 1.02 (1.01, 1.03) | 1.03 (1.01, 1.04) | 1.02 (1.01, 1.03) |
Change in pain VAS from week 36 to 40 | 1.03 (1.01, 1.04) | 1.05 (1.04, 1.07) | 1.03 (1.02, 1.03) |
Loss of DAS28 remission and change in DAS28 ≥ 0.6 in double-blind period | |||
Lack of sustained DAS28 remission | 2.82 (1.64, 4.85) | 2.59 (1.44, 4.66) | 1.98 (1.33, 2.96) |
Sustained weighted DAS28 remission | 0.68 (0.57, 0.82) | 0.68 (0.55, 0.83) | 0.78 (0.67, 0.91) |
DAS28 at week 36 | 1.21 (0.80, 1.83) | 2.04 (1.25, 3.34) | 1.35 (0.95, 1.90) |
DAS28 at week 40 | 3.55 (2.67, 4.71) | 7.18 (4.79, 10.75) | 2.65 (2.17, 3.23) |
Change in DAS28 from week 36 to 40 | 3.55 (2.67, 4.71) | 7.18 (4.79, 10.75) | 2.65 (2.17, 3.23) |
ESR at week 40 | 1.05 (1.02, 1.08) | 1.05 (1.02, 1.07) | 1.02 (1.01, 1.03) |
Change in ESR from week 36 to 40 | 1.09 (1.05, 1.12) | 1.07 (1.04, 1.10) | 1.02 (1.01, 1.03) |
Sustained weighted SDAI remission | 0.71 (0.49, 1.01) | 0.47 (0.30, 0.76) | 0.81 (0.60, 1.09) |
SDAI at week 40 | 1.13 (1.09, 1.18) | 1.29 (1.21, 1.38) | 1.10 (1.07, 1.12) |
Change in SDAI from week 36 to 40 | 1.15 (1.10, 1.20) | 1.26 (1.19, 1.34) | 1.11 (1.08, 1.14) |
Sustained weighted CDAI remission | 0.80 (0.58, 1.10) | 0.48 (0.31, 0.74) | 0.85 (0.64, 1.14) |
CDAI at week 40 | 1.13 (1.09, 1.18) | 1.28 (1.21, 1.36) | 1.10 (1.07, 1.13) |
Change in CDAI from week 36 to 40 | 1.14 (1.10, 1.19) | 1.26 (1.19, 1.34) | 1.11 (1.08, 1.14) |
HAQ at week 40 | 1.74 (1.08, 2.80) | 1.85 (1.15, 2.98) | 2.17 (1.55, 3.04) |
Change in HAQ from week 36 to 40 | 1.74 (0.85, 3.56) | 4.21 (2.11, 8.39) | 4.24 (2.61, 6.89) |
PGA at week 40 | 1.55 (1.26, 1.91) | 1.92 (1.54, 2.38) | 1.30 (1.18, 1.43) |
Change in PGA from week 36 to 40 | 1.70 (1.36, 2.11) | 1.60 (1.23, 2.08) | 1.30 (1.17, 1.43) |
PtGA at week 40 | 1.25 (1.12, 1.40) | 1.34 (1.17, 1.53) | 1.30 (1.20, 1.41) |
Change in PtGA from week 36 to 40 | 1.27 (1.12, 1.43) | 1.52 (1.27 1.82) | 1.35 (1.23, 1.47) |
General health at week 40 | 1.03 (1.01, 1.04) | 1.03 (1.01, 1.04) | 1.03 (1.01, 1.04) |
Change in general health from week 36 to 40 | 1.04 (1.02, 1.06) | 1.03 (1.02, 1.05) | 1.03 (1.02, 1.04) |
TJC at week 40 | 1.16 (1.10, 1.23) | 1.50 (1.34, 1.69) | 1.25 (1.17, 1.34) |
Change in TJC from week 36 to 40 | 1.16 (1.10, 1.23) | 1.59 (1.39, 1.80) | 1.28 (1.20, 1.37) |
SJC at week 40 | 1.18 (1.03, 1.34) | 1.51 (1.32, 1.73) | 1.17 (1.08, 1.26) |
Change in SJC from week 36 to 40 | 1.35 (1.16, 1.56) | 1.49 (1.27, 1.75) | 1.28 (1.17, 1.40) |
Pain VAS at week 40 | 1.02 (1.01, 1.03) | 1.03 (1.02, 1.05) | 1.02 (1.01, 1.03) |
Change in pain VAS from week 36 to 40 | 1.03 (1.01, 1.04) | 1.05 (1.03, 1.07) | 1.03, (1.02, 1.04) |
ETN 50 mg + MTX n = 72 | ETN 25 mg + MTX n = 60 | MTX n = 53 | |
Loss of SDAI remission at single time point in double-blind period | |||
Lack of sustained SDAI remission | 2.57 (0.90, 7.32) | 1.86 (0.55, 6.24) | 2.92 (1.08, 7.94) |
Sustained weighted SDAI remission | 0.67 (0.49, 0.90) | 0.62 (0.45, 0.86) | 0.68 (0.51, 0.90) |
SDAI at week 36 | 1.56 (1.06, 2.29) | 2.00 (1.34, 3.00) | 1.14 (0.80, 1.62) |
SDAI at week 40 | 1.13 (1.07, 1.19) | 1.18 (1.09, 1.29) | 1.05 (1.02, 1.08) |
Change in SDAI from week 36 to 40 | 1.13 (1.07, 1.19) | 1.18 (1.09, 1.29) | 1.05 (1.02, 1.08) |
Sustained weighted CDAI remission | 0.71 (0.53, 0.95) | 0.61 (0.44, 0.83) | 0.71 (0.54, 0.92) |
CDAI at week 40 | 1.12 (1.07, 1.18) | 1.18 (1.09, 1.29) | 1.05 (1.02, 1.08) |
Change in CDAI from week 36 to 40 | 1.12 (1.07, 1.18) | 1.19 (1.09, 1.29) | 1.05 (1.02, 1.08) |
Sustained weighted DAS28 remission | 0.81 (0.63, 1.03) | 0.93 (0.71, 1.22) | 0.86 (0.67, 1.10) |
DAS28 at week 40 | 1.76 (1.20, 2.59) | 1.70 (1.05, 2.77) | 1.46 (1.19, 1.79) |
Change in DAS28 from week 36 to 40 | 2.09 (1.47, 2.96) | 2.55 (1.52, 4.28) | 1.62 (1.24, 2.11) |
HAQ score at week 40 | 1.76 (0.90, 3.44) | 1.92 (0.86, 4.26) | 2.22 (1.17, 4.21) |
Change in HAQ score from week 36 to 40 | 2.66 (0.89, 7.96) | 6.13 (1.69, 22.26) | 4.25 (1.83, 9.91) |
PGA at week 40 | 1.77 (1.37, 2.29) | 1.79 (1.32, 2.42) | 1.27 (1.10, 1.47) |
Change in PGA from week 36 to 40 | 1.69 (1.33, 2.14) | 1.88 (1.30, 2.70) | 1.26 (1.09, 1.46) |
PtGA at week 40 | 1.37 (1.17, 1.61) | 1.72 (1.32, 2.24) | 1.30 (1.13, 1.50) |
Change in PtGA from week 36 to 40 | 1.40 (1.20, 1.64) | 1.73 (1.32, 2.27) | 1.30 (1.14, 1.50) |
General health VAS at week 40 | 1.04 (1.01, 1.07) | 1.04 (1.01, 1.06) | 1.02 (1.01, 1.04) |
Change in general health VAS from week 36 to 40 | 1.05 (1.02, 1.07) | 1.04, (1.01, 1.06) | 1.03 (1.01, 1.04) |
TJC at week 40 | 1.31 (1.10, 1.56) | 1.36 (1.11, 1.68) | 1.05 (1.00, 1.11) |
Change in TJC from week 36 to 40 | 1.38 (1.14, 1.67) | 1.38 (1.13, 1.69) | 1.06 (1.00, 1.12) |
SJC at week 40 | 1.31 (1.05, 1.63) | 1.15 (0.91, 1.44) | 1.17 (1.01, 1.36) |
Change in SJC from week 36 to 40 | 1.30 (1.04, 1.63) | 1.15 (0.93, 1.44) | 1.17 (1.01, 1.35) |
Pain VAS at week 40 | 1.03 (1.01, 1.05) | 1.05 (1.02, 1.08) | 1.03 (1.01, 1.04) |
Change in pain VAS from week 36 to 40 | 1.04 (1.02, 1.06) | 1.05 (1.03, 1.09) | 1.03 (1.01, 1.05) |
Loss of CDAI remission at single time point in double-blind period | |||
Lack of sustained CDAI remission | 2.10 (0.82, 5.40) | 2.82 (0.83, 9.55) | 2.60 (1.04, 6.48) |
Sustained weighted CDAI remission | 0.69 (0.51, 0.92) | 0.57 (0.42, 0.78) | 0.71 (0.55, 0.93) |
CDAI at week 36 | 1.49 (1.04, 2.15) | 1.65 (1.14, 2.39) | 1.07 (0.76, 1.51) |
CDAI at week 40 | 1.15 (1.09, 1.21) | 1.21 (1.11, 1.31) | 1.05 (1.02, 1.09) |
Change in CDAI from week 36 to 40 | 1.15 (1.09, 1.21) | 1.21 (1.11, 1.31) | 1.05 (1.02, 1.09) |
Sustained weighted SDAI remission | 0.63 (0.46, 0.87) | 0.59 (0.42, 0.81) | (0.68 (0.51, 0.90) |
Sustained weighted DAS28 remission | 0.78 (0.61, 1.00) | 0.96 (0.76, 1.22) | 0.81 (0.63, 1.04) |
DAS28 at week 40 | 1.95 (1.30, 2.91) | 2.12 (1.32, 3.38) | 1.51 (1.23, 1.86) |
Change in DAS28 from week 36 to 40 | 2.11 (1.47, 3.01) | 2.87 (1.77, 4.66) | 1.71 (1.31, 2.22) |
HAQ score at week 40 | 2.10 (1.10, 4.00) | 1.87 (0.85, 4.12) | 2.10 (1.10, 4.02) |
Change in HAQ score from week 36 to 40 | 4.00 (1.38, 11.62) | 10.88 (3.35, 35.34) | 4.34 (1.86, 10.12) |
PGA at week 40 | 1.93 (1.49, 2.49) | 1.90 (1.40, 2.56) | 1.30 (1.13, 1.50) |
Change in PGA from week 36 to 40 | 1.83 (1.42, 2.35) | 2.07 (1.48, 2.91) | 1.30 (1.12, 1.51) |
PtGA at week 40 | 1.45 (1.23, 1.70) | 1.82 (1.40, 2.37) | 1.32 (1.16, 1.51) |
Change in PtGA from week 36 to 40 | 1.46 (1.24, 1.72) | 1.75 (1.35, 2.28) | 1.34 (1.17, 1.53) |
General health VAS at week 40 | 1.05 (1.02, 1.08) | 1.04 (1.02, 1.06) | 1.03 (1.01, 1.04) |
Change in general health VAS from week 36 to 40 | 1.05 (1.03, 1.08) | 1.04 (1.02, 1.07) | 1.03 (1.01, 1.04) |
TJC at week 40 | 1.41 (1.18, 1.68) | 1.41 (1.15, 1.74) | 1.06 (1.01, 1.12) |
Change in TJC from week 36 to 40 | 1.50 (1.24, 1.82) | 1.45 (1.19, 1.76) | 1.07 (1.01, 1.13) |
SJC at week 40 | 1.40 (1.12, 1.74) | 1.19 (0.96, 1.49) | 1.20 (1.04, 1.39) |
Change in SJC from week 36 to 40 | 1.39 (1.10, 1.74) | 1.20 (0.97, 1.49) | 1.20 (1.04, 1.39) |
Pain VAS at week 40 | 1.04 (1.02, 1.06) | 1.05 (1.03, 1.08) | 1.03 (1.01, 1.04) |
Change in pain VAS from week 36 to 40 | 1.04 (1.02, 1.06) | 1.06 (1.03, 1.09) | 1.03 (1.02, 1.05) |